Introduction
Pulmonary arterial hypertension (PAH) is a rare but fatal disease, often of unknown origin, characterized by progressive increase in pulmonary vascular resistance and remodeling associated with vasoconstriction 1 . PAH is histologically characterized by a neomuscularization of small pulmonary arteries with intimal thickening, medial hypertrophy, adventitial proliferation, and abnormal extracellular matrix deposition. The progression of vascular remodeling results in vascular lumen narrowing, increased pulmonary artery resistance, hypoxia, and right heart hypertrophy, although the molecular pathways initiating this remodeling are not clearly established.
On the one hand, stem cells, resident or not, may give rise to a significant proportion of differentiating/proliferating smooth muscle cells (SMC) that contribute to intimal hyperplasia in lung vascular remodeling 2 . Moreover, genetic ablation of the transmembrane tyrosine kinase receptor for stem cell factor/c-kit pathway results in a marked reduction in intimal hyperplasia in animal models of vascular injury; conversely, wild-type (WT) bone-marrow reconstitution in c-kit mutant mice led to intimal hyperplasia comparable to WT animals 3 . Pharmacological antagonism of the c-kit pathway with STI-571 (imatinib mesylate-Gleevec) also results in a marked reduction in hyperplasia 3 . Mobilization of c-kit expressing cells from bone-marrow to blood circulation is a physiological response to hypoxia. Increasing evidence supports the idea that these progenitor cells of bone-marrow origin may also contribute to vascular wall remodeling that is characteristic of PAH [4] [5] [6] [7] [8] . It is unclear, however, whether this entry of progenitors represents a protective or a worsening process in the development of PAH 9 . Other observations have also identified an association between PAH and bone-marrow-related hematological disorders 10 : in proliferative disorders of the hematopoietic stem cells such as myeloproliferative cancers, there is a high unexplained incidence of PAH; PAH is now a recognized complication of bone-marrow transplantation for leukemia 11 , chronic myeloproliferative disorders 12 , or in the treatment of malignant infantile osteopetrosis 13 .
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On the other hand, serotonin (5-Hydroxytryptamine, 5-HT) is associated to the pathogenesis of PAH 14 . Therapeutic drugs with PAH as a side effect, like the amphetamine derivative and anorexigen dexfenfluramine, are potent 5-HT releasers acting at 5-HT transporter (SERT) and/or agonists at 5-HT receptors (5-HTRs) 15 . An over-expression of 5-HT 2B Rs is observed in PAH 16 . Blockade of 5-HT 2B Rs using independent approaches, either genetic (5-HT 2B R knockout mice; 5-HT 2B -/-) or pharmacologic (5-HT 2B antagonist RS-12744) inactivation, completely prevented the development of hypoxia-induced pulmonary hypertension in mice 16 . Using the monocrotaline (MCT)-induced pulmonary hypertension rat model, recent studies confirmed that other 5-HT 2B antagonists (terguride, PRX-08066, or C-122)
significantly reduced pulmonary pressure, arterial wall thickening and lumen occlusion but maintained cardiac function [17] [18] [19] . Independently, 5-HT was shown to stimulate human bone-marrow stromal cells and synergize with other pleiotropic growth factors that promote hematopoietic stem and progenitor cells 20 .
The 5-HT action on hematopoiesis or bone-marrow microenvironment at patho-physiological conditions warrant further investigation. 5-HT is a potent vasoconstrictor of pulmonary arteries but also to stimulate pulmonary SMC proliferation. It may thus affect various processes associated to pulmonary vascular remodeling, but its exact contribution remains unclear.
The prognosis of PAH remains unsatisfying 21 , although the number of therapeutic options has increased over the past years, and several novel therapeutic targets are under active investigation 1 . At present, currently available vasodilator therapies for PAH, although helpful in improving exercise tolerance and quality of life, are only moderately effective in improving survival. These therapies are targeted to ameliorate the physiologic consequences of the remodeled pulmonary arterial vasculature and probably do not directly alter the underlying defects in the pulmonary vascular remodeling. Here, we investigated a possible contribution of 5-HT signaling pathways to bone-marrow-derived progenitors cells in animal models of PAH. We found that the expression of 5-HT 2B Rs restricted to bone-marrow cells is necessary and sufficient for pulmonary hypertension to develop via an action at hematopoietic stem cells differentiation. antibody and the polyclonal rabbit anti-5-HT 2B R were from AbCam.
Animals.
The mice strains used in all experiments, including 5-HT 2B Rs deficient mice (5-HT 2B -/-) are in a 129S2/SvPAS background 22 . Adult (7-9 week-old) 5-HT 2B -/-, and wild-type (WT) control mice (originally obtained at Charles River Laboratories, L'Arbresle France) were all derived from heterozygote crosses bred at our animal facilities. All mice were maintained according to the EC directive 86/609/CEE, and housed in groups of 3-5 of the same genetic background after weaning.
Bone-marrow transplantation.
As previously described 23 , 6 males and 6 females 8 weeks-old WT and 5-HT 2B -/-mice were subjected to 9.5 Gray lethal total body irradiation. The day after, mice were reconstituted by direct intravenous injection with 2.5x10 6 cells of freshly isolated bone-marrow from femurs and tibias of age and sex-matched WT or 5-HT 2B -/-mice. All lethally irradiated and transplanted mice survived revealing the efficiency of bone-marrow reconstitution. After 4 weeks of recovery, transplanted mice were then exposed to hypoxia as a validated pulmonary hypertension inducer in mice.
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Pulmonary hypertension induction.
As previously observed 24 , following bone-marrow transplantation, mice were more sensitive to pulmonary hypertension inducers. Control and test mice were thus exposed to progressive hypoxia (20 to 10% O 2 ) for 3 weeks. Control, normoxic mice were kept in the same 12/12 light-dark cycle. The vehicle or drug was delivered by miniosmotic pump (Alzet) at the beginning of the hypoxic (or normoxic) treatment.
Cardiovascular evaluations.
As previously described 16 mice were anesthetized with intraperitoneal ketamine hydrochloride (60 mg/kg) and xylazine (8 mg/kg). The arterial pulmonary pressure was estimated by assessing the cardiac right ventricular systolic pressure (RVSP), measured by insertion into the heart right ventricle of a 26-gauge needle connected to a pressure transducer. The pulmonary artery was cannulated through an incision in the right ventricle and perfused with Earle's balanced salt solution (37°C, 20 cm H 2 O pressure). The heart and lungs were removed and the airways were distended with 10% formaldehyde solution and fixed for 3 days.
Measurements of the 5-HT 2B R expression was performed using 5-HT 2 R-specific iodinated radioligand ( 125 I-DOI) sensitive to RS 127445 as previously described 22 .
Cell preparations, FACS analysis and sorting.
Murine bone-marrow cells were recovered and suspended in culture medium, as described 25 . Briefly, bonemarrow cells, flushed from femur and tibia, were resuspended in Hank's buffer before being passed through a 70μm strainer. Cells were then incubated with appropriately labeled antibodies (CD11b, Gr1, CD31, c-kit 
Cell cultures
Murine hematopoietic progenitors were quantified in MethoCult M3334 (StemCell Technologies) supplemented with IL-3, IL-6, SCF and in MethoCult GF H4434 (complete with growth factors), respectively. Cells were plated in a final volume of 1 ml at a concentration of 2-5×10 4 total BM cells/culture dish (Falcon 1008) for murine and 5000 CD34+ cells/ml for human progenitors. Colonies were scored on day 7 and day 14. All cultures were incubated at 37°C in a humidified chamber under 5% CO2.
For methylcellulose cultures, human CD34+ cells were cultured in BFU-E/CFU-E medium with EPO, IL-3, SCF (Stem Cell 4434) and murine total or c-kit + cells were cultured in CFU-GEMM/CFU-GM, and CFU-E/BFU-E medium with IL-3, IL-6, SCF, and EPO (Stem Cell 03434).
Statistics.
The reported data represent the mean of individual values ± SEM (n = number of individuals at the end of treatments as indicated in the text). For simple comparisons, unpaired t test was used. Significance was set at P < 0.05. For the groups, statistical comparisons were made by one way ANOVA. When statistical significance was attained (P < 0.05), difference between groups was established using the Bonferroni multiple comparison test.
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Results
Alterations of blood composition in 5-HT 2B R mutant mice. Starting from the previous observations that 5-HT may act on hematopoiesis 20 , we first investigated the blood composition of WT and 5-HT 2B -/-mice.
Interestingly, we found a significant decrease in platelet number and increase in circulating granulocyte / macrophage population in 5-HT 2B -/-compared to WT mice, but not in other parameters, white blood cells, red blood cells, mean red blood cell volume, hematocrit, or hemoglobin content (Fig 1a) . Flow cytometric cell sorting (FACS) was performed using antibodies to identify different populations, Mac-1 (CD11b) for monocytes / macrophages, Gr-1 (Gr+) for Granulocytes, PECAM (CD31) for endothelial cells / platelets / macrophages and determine the blood cell composition of WT and 5-HT 2B -/-mice. Completing our previous result, we found a significant reduction in CD11b-/CD31+ population that labeled immature endothelial progenitor cells in 5-HT 2B -/-mice (Fig 1b) . Interestingly, by FACS of peripheral blood mononuclear cells,
we also identified expression of 5-HT 2B Rs in c-kit + (CD117 positive) cells. Importantly, c-kit negative cells were negative for 5-HT 2B R expression (Fig 1c) . Together, these observations support that 5-HT 2B Rs may affect the differentiation of hematopoietic and bone-marrow precursor cells.
Alterations of bone-marrow composition in 5-HT 2B R mutant mice. From these blood defects in 5-HT 2B
-/-mice, we could expect associated alterations in bone-marrow cell composition. Using FACS analysis, we determined the bone-marrow composition of WT and 5-HT 2B -/-mice (Fig 2) . In accordance with our blood results, we found in 5-HT 2B R mutant bone-marrow a significant increase in Cd11b+/Gr+ that represents granulocyte precursors (Fig 2a) . Interestingly, this was associated with a significant reduction in Cd11b-/Cd31+ population that labeled immature endothelial progenitor cells in 5-HT 2B -/-mice (Fig 2d) . Together, these observations support that the lack of 5-HT 2B Rs alters the differentiation of myeloid precursor cells; these precursors may be required for endothelial progenitor cells that have been proposed to participate to the development of pulmonary hypertension and pulmonary vascular remodeling 26 .
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Mice with restricted ablation of 5-HT 2B Rs to bone-marrow are resistant to pulmonary hypertension.
We investigated if 5-HT 2B Rs interact with bone-marrow derived stem cells in the development of pulmonary hypertension. For this, we generated mice with restricted deletion or rescue of 5-HT 2B Rs in bone-marrow cells using lethal total body irradiation to eliminate all stem cells combined to bone-marrow transplantation (Fig 3a-Methods -Supplementary Methods) . Strikingly, following this procedure, we found that only mice transplanted with WT bone-marrow (i.e. expressing 5-HT 2B Rs) responded to chronic hypoxia in increasing their pulmonary arterial pressure as measured in the heart by the right ventricular systolic pressure (RVSP). Irradiated mice transplanted with WT bone-marrow presented a significant increase in RVSP, including 5-HT 2B -/-host mice after 3 weeks of hypoxia. By contrast, all mice having received bone-marrow from 5-HT 2B -/-mice, were completely insensitive to hypoxia and never showed any sign of RVSP increase, including WT host mice (Fig 3b) . Mice with restricted 5-HT 2B R deletion to bonemarrow thus behaved as RS-127445-treated WT, or full 5-HT 2B -/-mice 16 . To exclude putative bias in these results due to the hypoxic model of pulmonary hypertension, we tested the effects of bone-marrow transplantation using another animal model of pulmonary hypertension induced by a single MCT injection.
Strictly similar results were obtained in MCT injected mice: only mice with 5-HT 2B R expressing WT bonemarrow developed an increase in RVSP (Fig S1) . These results support a need for 5-HT 2B R-dependent processes in bone-marrow for the development of pulmonary hypertension.
Lung 5-HT 2B R-and c-kit-expressing cells are of bone-marrow origin. Since an increase in lung 5-HT 2B R expression had been previously documented in PAH 16, 17 , we tested lung 5-HT 2B R expression after irradiation and bone-marrow replacement. Noteworthy, irradiated 5-HT 2B -/-mice having received WT bonemarrow and exposed to hypoxia showed a similar increase in lung 5-HT 2B R expression (about 7 fold) as irradiated WT host mice having received WT bone-marrow (Fig 3c-d) . To the opposite, WT mice having Fig S1) . These results support that lung cells overexpressing 5-HT 2B Rs during pulmonary hypertension are originating from bone-marrow precursors and not from lung resident cells.
Since c-kit has been shown to be expressed in lungs of PAH patients 26, 27 , we completed these investigations by performing c-kit and 5-HT 2B R immuno-histochemistry of lung tissues. Interestingly, a partially overlapping increase in both c-kit and 5-HT 2B R expression was observed in small arteries of hypoxic WT or 5-HT 2B -/-mice transplanted with 5-HT 2B R expressing WT bone-marrow, but not with 5-HT 2B -/-bone-marrow (Fig 3c-e) . was used in methylcellulose colony-forming assay, we observed a significant reduction in both CFU-GEMM/CFU-GM and CFU-E/BFU-E colonies with the 5-HT 2B R antagonist (Fig. 4a) . Similar results were obtained when analyzing the clonogenic potential of isolated c-kit + cells from mice bone-marrow that showed also a reduction in both CFU-GEMM/CFU-GM and CFU-E/BFU-E colonies with the 5-HT 2B R antagonist (Fig. 4b) . To validate these findings in humans, we then analyzed the clonogenic potential of (Fig 4d) . Interestingly, in cultures performed in the presence of GM-CSF, we found that the lack of 5-HT 2B R reduced the apparition of granulocyte precursors (CD11b+/Gr+) lineage by 50% (Fig 4e) . Since GM-CSF controls the differentiation of monocyte/macrophages and all granulocytes 29 Blocking tyrosine kinase c-kit activity prevents pulmonary hypertension and 5-HT 2B R overexpression. Among compounds that are under investigation for PAH treatment, the tyrosine kinase inhibitor, STI-571 has been shown to be effective 30 . We thus compared the 5-HT 2B selective antagonist RS-127445 with STI-571 in their ability to prevent pulmonary hypertension in the mouse hypoxic model and found they were both equally effective for tested parameters (Fig. 5a, Fig S2a-d) . However, we found that only STI-571 was able to prevent the increase in lung 5-HT 2B R expression (Fig. 5b) . We therefore investigated the kinetic in establishment of hypoxic pulmonary hypertension with that of 5-HT 2B R overexpression. Interestingly, we found that STI-571 was able to prevent both the increase in RVSP and the Launay p12 5-HT 2B R overexpression with similar kinetic (Fig 5c,d) . These results support an action of both inhibitors at a common pathway that ultimately participate in the pulmonary hypertension pathogenesis.
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Discussion
Both 5-HT and bone-marrow-derived stem cells have been shown to participate to some extent in PAH. Our work establishes, for the first time, a causal link between these two issues by showing (i) the initial functions in pulmonary hypertension of 5-HT 2B R restricted to bone-marrow cells, (ii) the contribution to stem cells differentiation/proliferation of 5-HT 2B Rs, and (iii) the critical functions of bone-marrow-derived cells for pulmonary hypertension development.
Several independent investigations have described a mobilization of bone-marrow-derived cells during pulmonary hypertension 2 . Not only cells expressing c-kit are mobilized from bone-marrow in the circulation in response to hypoxia, but they are also found in the remodeled lung vessel wall in PAH ( 7, 8, 12, 24, 31 and Fig 3) . Activation of c-kit was reported as necessary for mobilization of reparative bonemarrow progenitor cells 32 and for the remodeling of blood vessels from these progenitor cells 3, 27 .
Recently, a role of c-kit + progenitors in hypoxia-induced vascular remodeling 26, 33 was evidenced: stromal derived factor-1 (SDF-1/CXCL12) and its receptors CXCR4 and CXCR7 have been shown to be critical for homing of hematopoietic c-kit + progenitor cells in the perivascular niche, including in chronic hypoxiaexposed mice. These mice showed increased lung expression of CXCR4, CXCR7 and CXCL12, associated with significantly increased RVSP, vascular remodeling and perivascular c-kit 26 . In humans, pulmonary arterial lesions are also associated with expression of CXL12 that may recruit c-kit + cells 27 . As we previously reported 16 , 5-HT 2B Rs were found overexpressed (as in mice)
on human vascular SMC layer in lungs from PAH patients and at least partially colocalized with SMC alpha-actin 17 . Independently, c-kit was shown to colocalize partially with SMC alpha-actin 26 . We show,
here, that c-kit and 5-HT 2B R staining are also partially overlapping in hypoxic lung arteries, supporting a common link to SMC lineage. Further work will be need in order to clarified the exact contribution of these different partners into vascular remodeling during PAH. Although likely not instructive in stem cell lineages, 5-HT may rather modulate the balance between different lineages by participating at the proliferation and/or survival of specific lineage via its receptors (Fig 6) . Similar to what we found here using 5-HT 2B R antagonist RS-127445, a decrease in colony-forming capacity was observed with STI-571 with inhibition of both CFU-GEMM and BFU-E formation attributed to a reduction of cell proliferation and/or an apoptotic effect 39 . In addition, we found 5-HT 2B R expression . We previously showed that 5-HT 2B Rs were required for proliferation of embryonic and survival of newborn cardiomyocytes via regulation of mitochondrial membrane permeability, caspase activation, and Akt/ERK1/2 pathways 42 . Combined with these observations, the present data clearly highlight the importance of 5-HT via 5-HT 2B Rs at various levels of the myeloid lineages as summarized on the scheme (Fig 6) . Our data support their requirement for proliferation/survival after the c-kit-dependent mobilization of precursors from bone-marrow.
Bone-marrow progenitor cell mobilization is a physiological response to hypoxic conditions 4, 6 , and altered circulating bone-marrow-derived precursors have been reported in PAH as contributors to vascular remodeling 7, 8, 24, 31 . Patients with myeloproliferative diseases often develop PAH, but this secondary form of PAH has been reported to resolve with treatment of the underlying myeloproliferative process 43 . Other data Launay p16 highlight a potential interdependence of dysregulated hematopoiesis and abnormal pulmonary vascular endothelial behavior that may play a key role in the development of PAH 10 . It was previously demonstrated that cells from the mononuclear lineage could differentiate into endothelial-and SMC-like cells at injured vessels [44] [45] [46] [47] and that circulating precursors of this lineage can contribute to hypoxia-induced pulmonary vascular remodeling 6 . In this context, a stimulus-dependent generation of pro-angiogenic and bonemarrow-derived early progenitors could be required for physiological repair response to ongoing pulmonary vascular shear stress and endothelial injury. That this process ultimately contribute to the abnormal proliferation of SMC and endothelial cells leading to progression of pulmonary hypertension was still hypothetical 9 . We validate here the interdependence of dysregulated hematopoiesis and abnormal pulmonary vascular remodeling that play key roles in the development of PAH. 
